Plasmin, a directly acting thrombolytic agent, demonstrated a very favorable safety profile upon intra-arterial delivery to the clot site; however, its thrombolytic efficacy remains to be further assessed. In this study, differences in thrombolysis between clots exposed to equimolar concentrations of plasmin and recombinant tissue-type plasminogen activator (rt-PA) after partial vessel recanalization were tested in a model system. Model blood clots were prepared in glass chambers enabling direct observation by dynamic optical microscopy. The incubation of clots with plasmin (2.4 mg/ ml) or rt-PA (2.63 mg/ml), allowing for the initial biochemical clot degradation, was followed by 'flushing' the clots with tangentially directed plasma flow devoid of a thrombolytic agent, mimicking blood flow after partial vessel recanalization. The acquired images were analyzed for nondissolved blood clot area as a function of time. With both thrombolytic agents, the relative clot area decreased rapidly in the first 30 s after initiation of perfusion due to 'flushing' the degraded clot fragments (after plasmin by 0.26 W 0.22 and after rt-PA by 0.34 W 0.21, P U 0.60). In the following minutes, the clot size showed a linear time dependence: after incubation with plasmin the clot size did not change substantially any more, whereas after incubation with rt-PA the clot size continually decreased. The slopes of the regression lines differed significantly (r pl U S8.9 10 S3 vs. r rtPA U S44
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Introduction
Recombinant tissue-type plasminogen activator (rt-PA) is nowadays an accepted and widely used thrombolytic agent in clinical treatment of thrombotic complications [1] . It is an efficient thrombolytic agent; however, its activity is not limited only to the site of the thrombus even if administered locally. Often, as a side effect, the application of rt-PA may result in bleedings at sites of hemostatic plugs [2] . Therefore, its use is contraindicated in hemorrhagic stroke and head trauma. Because of the danger of systemic bleeding, rt-PA cannot be considered as a completely well tolerated thrombolytic agent.
The danger can be avoided by the use of a different type of thrombolytic agent with activity limited only to the site of its application, such as plasmin. Plasmin can be delivered by catheter to the site of vessel obstruction and is then rapidly inactivated by a-2-antiplasmin and a-2-macroglobulin upon entering the systemic circulation [1, 2] . Plasmin has been tested for safety in animal models [3, 4] and phase I clinical trials [5] [6] [7] , but there is limited data on its efficacy. In the recently completed phase I clinical trial in patients with peripheral artery or bypass graft occlusions, substantial thrombolysis (! 50%) occurred in 79% of patients receiving 125-175 mg of plasmin, as compared to 50% who received 25-100 mg [6] . The effective dose of plasmin was thus more than three times greater than the total administered dose of rt-PA, which rarely exceeds 40 mg for catheter directed thrombolysis of peripheral arterial occlusions. This poses the question, whether the thrombolytic efficacy of plasmin is lost after partial vessel recanalization occurs.
The aim of this study was to employ our recently developed micro-perfusion system with dynamic optical microscopy imaging to study the differences in dissolution dynamics between plasmin and rt-PA. Specifically, we tested whether thrombolysis continues after incubation of blood clots with equimolar concentrations of plasmin or rt-PA when tangential plasma flow is initiated, mimicking partial vessel recanalization.
Materials and methods

Blood clot preparation
Blood was collected from the cubital veins from healthy volunteers under standardized conditions into 4.5 ml vials (Vacutainer; Becton-Dickinson, Germany) containing 0.45 ml of 0.129 mol/l Na-citrate. Blood clots were prepared in an observation chamber (Fig. 1a) specially designed for optical microscopy. Approximately 20% of the chamber volume was filled with 50 ml of blood with added 100 mg/ml of thrombin (Thrombin; Sigma, Germany) to a final concentration of 1.37 NIH unit/ml. Blood with thrombin was allowed to spontaneously retract in the chamber for 2 h at the room temperature (248C).
Thrombolysis
The perfusion system consisted of an observation chamber with the clot that was connected to a precision peristaltic pump designed for optical chromatography (LKB BrommaHPLC 2249; Uppsala, Sweden) and of a reservoir filled with 30 ml of thermoregulated blood plasma (378C) (Fig. 1b) . Plasmin (Human, BAY-57-9602), kindly provided by Grifols, Research Triangle Park, North Carolina, USA, was dissolved with distilled water to a concentration of 5 mg/ml and aliquots frozen at À808C until use. Immediately before experiments, the stock solution was thawed and diluted to 2.40 mg/ml with 0.9% sodium chloride. The rt-PA (Actilyse; Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany) was diluted with 0.9% sodium chloride to 5 mg/ml and aliquots frozen at À808C until use. Immediately before experiments, the stock solution was thawed and diluted to 2.63 mg/ml with 0.9% sodium chloride. First, each clot was exposed to a thrombolytic agent, either plasmin in concentration of 2.40 mg/ml or rt-PA in equimolar concentration (2.63 mg/ml), in physiological salt solution or to a control (physiological salt solution only) for the incubation period of 10 min. This was followed by 10 min perfusion with blood plasma with a flow rate of 10 ml/min. The outdated plasma was thawed at room temperature and then warmed to 378C. All experiments were performed in triplicate.
Optical microscopy
The observation chamber with the model clot was placed under an optical microscope (Nikon 80i Eclipse) with a Nikon 10 Â Plan Flour objective (numerical aperture 0.3, working distance 16 mm). The microscope was equipped with a stroboscopic light producing 30 ms flashes of light every 2 s. The flashes of light were synchronized with image acquisition that was done by a digital camera (Nikon DS-Fi1) connected to the optical microscope. The entire thrombolytic procedure, consisting of 10 min incubation and 10 min perfusion, was dynamically imaged by the camera and stored to a personal computer running the Nikon NIS Elements software package for image acquisition and image processing. The imaging matrix was 640 Â 480 with resolution of 1.3 mm per pixel that corresponded to a field of view (FOV) of 823 Â 624 mm.
Image analysis
Sets of acquired images were analyzed for a nondissolved blood clot area as a function of time. The initial clot region occupied approximately 90% of FOV. The analysis of the nondissolved blood clot area was made by the ImageJ program (NIH, USA). First, images were converted into an 8-bit gray scale. This was followed by determination of average blood plasma brightness and setting of the threshold value to 50% of the brightness. All image pixels with intensity below the threshold value were assigned to the clot region, while the remaining pixels were assigned to the plasma region. Normalized nondissolved blood clot area as a function of time was calculated as ratios between the current and initial clot area thus obtaining individual clot dissolution curves.
Mathematical model
Experimental clot dissolution curves were analyzed with the corresponding model for clot dissolution. In the model clot area is constant during the incubation period T and then suddenly drops for DCD and starts decreasing with a rate r. Model parameters (DCD and r) were determined from the best fit between the model and the experimental clot dissolution curve for each of the two thrombolytic agents and the control, while the parameter T was set to 10 min (incubation time). The analysis was performed by the Origin software package (Origin Lab Corporation, Northampton, Massachusetts, USA).
Statistical analysis
Differences in the relative clot size after the first 30 s of perfusion were tested by the two-tailed Student's t-test. Differences between the linear regression slopes of the experimental clot dissolution curves of plasmin and rt-PA in the time interval 10.5-13.5 min were analyzed for statistical significance by the linear mixed model using the R software, version 2.15. Values below 0.05 were considered statistically significant.
Results Figure 2 shows the experimental data and the corresponding best-fit linear model of clot dissolution curves for both thrombolytic agents and the control experiment (incubation without a thrombolytic agent). Error bars represent the average SD for the entire data set. The curves have two distinct parts; the first corresponds to the 10 min incubation period, while the second corresponds to the 10 min clot perfusion. The corresponding best-fit model parameters, DCD and r, for each experimental clot dissolution curve are given in Table 1 .
During the incubation period the clot area did not change substantially. In the first 30 s after initiation of tangentially oriented perfusion a rapid decrease in the clot area (DCD) was observed with both thrombolytic agents. The magnitude of the initial decrease did not differ significantly between plasmin and rt-PA: 0.26 AE 0.22 vs. 0.34 AE 0.21, P ¼ 0.60. The initial 30 s phase was followed by an approximately linear clot dissolution curve with a constant slope r. After incubation with plasmin the slope r pl ¼ À8.9 10 À3 /min was significantly smaller than after rt-PA with r rtPA ¼ À44.1 10À3 /min, P < 0.01 (Table 1) .
Discussion
In this study, we employed the recently developed micro-perfusion system with dynamic optical microscopy imaging to study the differences in dissolution dynamics between equimolar doses of plasmin and rt-PA after partial vessel recanalization. Retracted whole blood clots served as a reproducible model for thrombi that are poorly susceptible to thrombolysis [8] . The intrathrombic injection of a thrombolytic agent was simulated by incubating the clot with the thrombolytic agents in the perfusion chamber in the absence of flow, while blood flow along the partly dissolved clot was simulated by perfusion of blood plasma tangentially to the surface of the clot.
Equimolar concentrations of plasmin (2.40 mg/ml) and rt-PA (2.63 mg/ml) were chosen for comparison because they belong into the high range of therapeutically achievable concentrations with local intrathrombic injection [6] . Systemic thrombolysis with plasmin is not used clinically, but would in theory be feasible with free plasmin activity of about 0.1-0.2 U/ml, 1 U/ml being the maximally obtainable plasmin activity in plasma [9] . The 10 min incubation time for the small, model blood clots was chosen on the basis of our preliminary experiments and because early thrombolytic effects in large, arterial thrombi become angiographically evident in less than 30 min [10] . Due to technical limitations, perfusion with blood plasma was laminar, not pulsatile as in the arterial system, and the generated shear forces were more similar to the venous than the arterial system [11] , but similar experimental conditions have been used previously to demonstrate the interplay between biochemical and biophysical factors in thrombolysis [11] . In order to simulate thrombolysis at body temperature we performed our
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The rapid decrease in the relative clot area at the beginning of perfusion, after incubation with either of the two tested thrombolytic agents, was associated with removal of the dissolved blood clot region by mechanical forces of streaming blood plasma [13] . The rate of the initial degradation did not differ significantly between plasmin and rt-PA which is in accordance with a previous report not showing differences in fibrinolytic efficacy of equimolar amounts of plasmin and rt-PA in ex vivo cerebral thrombi under no-flow conditions [14] .
Our experiments focused on the clot size after the initial 30 s of perfusion that removed the biochemically induced degradation products from the clot surface. After incubation with plasmin and the initial 'flushing', the process of clot degradation was practically completely stopped (low plasmin dissolution rate r pl , Table 1 ), which is likely due to complete inhibition of plasmin by its plasma inhibitors [15] . On the contrary, in the case of rt-PA, which binds to fibrin [16] , the perfusing plasma was supplying the clot with fresh plasminogen, which was then activated by rt-PA inside the clot and contributed to ongoing thrombolysis. This phenomenon likely occurs in vivo after partial clot recanalization and might explain why the total dose of plasmin needs to be quite high to achieve a good thrombolytic effect in the majority of patients with occluded femoropopliteal bypass grafts [7] .
In conclusion, we demonstrated significant differences between the dynamics of thrombolysis with plasmin and rt-PA after tangential plasma flow is established. The contact with flowing blood plasma terminates the thrombolytic action of plasmin while it allows for substantial residual action of rt-PA
